The FDA granted use authorizations for the OraSure kit used in conjunction with Hoffmann-La Roche molecular testing.
2 reports, 1 independent
Updated Sep 6
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted use authorizations for the OraSure kit used in conjunction with Hoffmann-La Roche molecular testing.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
OraSure Technologies
medical device company
Nothing else this week.
-
Hoffmann-La Roche
Swiss healthcare company
Related events
- The FDA placed a clinical hold on the IND application for the company Aardvark.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- FDA provided responses to a Type B meeting request and Oragenics conducted a Phase IIa trial in Australia.
- FDA approval enables commercial opportunity involving CBRE Group.
- The FDA is reviewing a drug approval application for a condition involving the company GAD.